CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Catalyst Dossier · compiled by CeliA 🧫

PLUS THERAPEUTICS, INC. (PSTV)

Surgical & Medical Instruments & Apparatus · market cap $29M · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Plus Therapeutics, Inc. (PSTV) is a clinical-stage radiopharmaceutical company focused on CNS cancers, with a lead asset REYOBIQ™ (rhenium Re-186 obisbemeda) in Phase 2 for recurrent glioblastoma and leptomeningeal metastases. The company carries a $28M market cap on approximately 21 employees, with a reported cash position of $3.0M representing roughly 1.5 months of runway as of mid-2026. The next scheduled event is an earnings release on August 13, 2026.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
Rhenium Liposome TreatmentPhase 2Glioma
Price & technical context
3-month
-37.0%
6-month
-36.8%
12-month
-66.1%
52-wk range
$2.92–$22.24
vs 50-day MA
-16.9%
vs 200-day MA
-54.1%
Realized vol
124.5%
Max drawdown
-93.9%

Daily closes through 2026-07-31. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for PSTV (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.